Ezetimibe vs Pitavastatin
FDA Approved vs FDA Approved
synergistic Researched · 95% Pitavastatin and ezetimibe act on complementary cholesterol pathways — pitavastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination provides an additional 15-20% LDL reduction beyond pitavastatin monotherapy. This pairing preserves pitavastatin's low interaction profile since ezetimibe is also minimally metabolized by CYP enzymes. Particularly useful for AAS users who need greater LDL reduction without switching to a higher-interaction statin.
Molecular Data
Ezetimibe Pitavastatin
Weight 409.43 Da 421.46 Da
Half-life ~22 hours ~12 hours
Type Azetidinone (C24H21F2NO3) Synthetic statin (C25H24FNO4)
Key Benefits
Ezetimibe
01 Reduces LDL cholesterol by 15-20% as monotherapy
02 Complementary mechanism to statins allows additive LDL reduction of 25% when combined
03 Minimal hepatotoxicity, making it suitable alongside hepatotoxic oral AAS
04 Simple once-daily dosing with no titration required
05 No significant impact on CoQ10 levels (unlike statins)
06 Well tolerated with a side effect profile comparable to placebo in clinical trials
07 Proven cardiovascular outcome benefit when added to statin therapy (IMPROVE-IT trial)
08 Helps manage the severe lipid disruption caused by oral steroids like Anavar and Winstrol
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Side Effects
Ezetimibe
Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo
Upper respiratory tract infection (reported in clinical trials but not clearly drug-related)
Fatigue and headache (uncommon, typically transient)
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Contraindications
Known hypersensitivity to ezetimibe or any component of the formulation
Active liver disease or unexplained persistent elevations in hepatic transaminases (when combined with a statin)
Pregnancy and breastfeeding (when used in combination with a statin)
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Research Evidence
Ezetimibe Pitavastatin
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.